nivolumab,ipilimumab,sunitinib
bms,pfizer
['gu ', 'cm 214', 'hcrn,gu16,260', '/ipi', 'hcrn,gu,16,260', 'rcc,(-irccs),(-srcc),(-urcc)', 'ca,209,214', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ca209,669', 'nivo', 'bms']
hcrn gu16-260 cohort a (ccrcc): 1l nivo, followed by nivo/ipi escalation if sd/pd 3-yr os: imdc fav (97%), int/poor (57%) 3-yr pfs: fav (31%), int (7%), poor (15%) treatment-free survival (tfs): 9.4 mo; fav (13 mo), int/poor (8 mo).
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology